1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Epiomic Epidemiology Series: Gaucher’s Disease Forecast in 9 Major Markets 2015-2025

Summary

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Gaucher’s Disease in 9 Major Markets

Gaucher’s Disease (GD) is caused by an inherited, autosomal recessive mutation in the GBA gene. This gene is responsible for providing the instructions for the production of the enzyme glucocerebrosidase. Without this enzyme, glucocerebroside and other similar substances can accumulate in macrophages and monocytes (white blood cells) and are deposited in various organs, including the spleen, liver, kidneys and lungs. This build-up can reach toxic levels which results in organ and tissue damage. This report provides the current prevalent population for GD across 9 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil, Japan and India) split by gender and 5-year age cohort. Along with the current prevalence, the report provides an overview of the types, occlusion locations and the prevalence of associated disorders of GD. The report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of GD have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for GD include:

-Splenomegally
-Hepatomegally
-Haematological conditions
-Musculoskeletal conditions
-Gall stones

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

-Able to quantify patient populations in global GD’s market to target the development of future products, pricing strategies and launch plans.
-Gain further insight into the prevalence of the subdivided types of GD and identify patient segments with high potential.
-Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
-Provide a level of understanding on the impact from specific co-morbid conditions on GD’s prevalent population.
-Examination of the prevalence of the different causative gene mutations for GD.
-Identify sub-populations within GD which require treatment.
-Gain an understanding of the specific markets that have the largest number of GD patients.

Table Of Contents

Epiomic Epidemiology Series: Gaucher’s Disease Forecast in 9 Major Markets 2015-2025
Gaucher's Disease
Table of Contents
-List of Tables and Figures
-Introduction
-Cause of the Disease
-Risk Factors and Prevention
-Diagnosis of the Disease
-Variation by Geography /Ethnicity
-Disease Prognosis and Clinical Course
-Key Co-Morbid Conditions / Features Associated with the Disease
-Methodology for Quantifications of Patient Number
-Top Line Prevalence for Gaucher's Disease (GD)
-Main Complications and Features of GD
o Phenotypic Sub-type of GD Patients
o Genotype of Type I GD Patients
o Genotype of Type III GD Patients
o Musculoskeletal Complications of GD
o Haematological Involvement of GD
-References
-Appendix

List of Tables and Figures
-Prevalence of GD, total (000s)
-Prevalence of GD, males (000s)
-Prevalence of GD, females (000s)
-GD by Phenotypic sub-Type, total (000s)
-Genotype of Type I GD Patients, total (000s)
-Genotype of Type III GD Patients, total (000s)
-Bone and Joint Pain in Patients with GD, total (000s)
-Radiological Bone Disease in Patients with GD, total (000s)
-Erlenmeyer Flask Deformity in Patients with Type I GD, total (000s)
-Presence of Anaemia in Patients with GD, total (000s)
-Presence of Thrombocytopenia in Patients with GD, total (000s)
-Presence of Bleeding Tendencies in Patients with GD, total (000s)
-USA Prevalence of GD by 5-yr age cohort, males (000s)
-USA Prevalence of GD by 5-yr age cohort, females (000s)
-France Prevalence of GD by 5-yr age cohort, males (000s)
-France Prevalence of GD by 5-yr age cohort, females (000s)
-Germany Prevalence of GD by 5-yr age cohort, males (000s)
-Germany Prevalence of GD by 5-yr age cohort, females (000s)
-Italy Prevalence of GD by 5-yr age cohort, males (000s)
-Italy Prevalence of GD by 5-yr age cohort, females (000s)
-Spain Prevalence of GD by 5-yr age cohort, males (000s)
-Spain Prevalence of GD by 5-yr age cohort, females (000s)
-United Kingdom Prevalence of GD by 5-yr age cohort, males (000s)
-United Kingdom Prevalence of GD by 5-yr age cohort, females (000s)
-Brazil Prevalence of GD by 5-yr age cohort, males (000s)
-Brazil Prevalence of GD by 5-yr age cohort, females (000s)
-Japan Prevalence of GD by 5-yr age cohort, males (000s)
-Japan Prevalence of GD by 5-yr age cohort, females (000s)
-India Prevalence of GD by 5-yr age cohort, males (000s)
-India Prevalence of GD by 5-yr age cohort, females (000s)

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
2016 Virology and Bacteriology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales and Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

2016 Virology and Bacteriology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales and Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

  • $ 54501
  • Industry report
  • October 2016
  • by Venture Planning Group

This unique 33-country survey from VPGMarketResearch.com contains over 2,100 pages, 875 tables and provides data and analysis not available from any other published source. The survey is designed to assist ...

2016 Infectious Disease Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

2016 Infectious Disease Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

  • $ 54501
  • Industry report
  • October 2016
  • by Venture Planning Group

This unique 33-country survey from VPGMarketResearch.com contains over 2,100 pages, 875 tables and provides data and analysis not available from any other published source. The survey is designed to assist ...

2016 Microbiology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Molecular Diagnostic, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, and Immunodiagnostic Tests

2016 Microbiology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Molecular Diagnostic, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, and Immunodiagnostic Tests

  • $ 47500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,000 pages and 550 tables, and provides granular data and analysis not available from any other published source. The survey is designed ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.